Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 1/20 | 0.34 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12346583 | 0.83 | NUDT1 (0.48) | NUDT1CYP1A2CLK4CYP3A4CYP2C19 | |
| SCHEMBL2235109 | 0.81 | NUDT1 (0.41) | NUDT1CYP1A2CLK4CYP3A4CYP2C19 | |
| SCHEMBL2231251 | 0.81 | CYP1A2 (0.57) | CYP1A2CLK4CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL2231023 | 0.78 | PIM1 (0.41) | CYP1A2CLK4CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL2348570 | 0.77 | CYP1A2 (0.41) | CYP1A2CLK4CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL2231287 | 0.75 | ACVR2A (0.39) | CYP1A2CYP3A4CYP2C19CYP2D6DYRK1A | |
| SCHEMBL2233315 | 0.74 | JAK2 (0.52) | JAK3 | |
| SCHEMBL2233311 | 0.74 | JAK2 (0.52) | JAK3 | |
| SCHEMBL2230590 | 0.73 | DYRK1A (0.35) | CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1 | |
| SCHEMBL2348079 | 0.73 | RPS6KA5 (0.42) | CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | claimed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | claimed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | claimed |
| EP-2536728-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-12-26 | — | — | EP | claimed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | claimed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| EP-2536728-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | NUDT1 830/4885CYP1A2 530/4885CLK4 1966/4885 |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | NUDT1 2235/4885CYP1A2 471/4885CLK4 2457/4885 |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | NUDT1 2235/4885CYP1A2 471/4885CLK4 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.